AIM ImmunoTech (AIM)
(Delayed Data from AMEX)
$0.27 USD
-0.02 (-8.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.24 -0.03 (-10.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMAIM ImmunoTech Inc. (AIM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.50 | $5.00 | $2.00 | 1,106.90% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for AIM ImmunoTech Inc. comes to $3.50. The forecasts range from a low of $2.00 to a high of $5.00. The average price target represents an increase of 1% from the last closing price of $0.29.
Analyst Price Targets (3 )
Broker Rating
AIM ImmunoTech Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/3/2024 | Ascendiant Capital Markets | Edward M Woo | Not Available | Moderate Buy |
4/12/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
2/1/2024 | Alliance Global Partners | James Molloy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $3.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | NA |